Published in
Springer Verlag, Clinical Rheumatology, 9(31), p. 1289-1292
DOI: 10.1007/s10067-012-2066-5
Links
Tools
Subsequent entry biologics/biosimilars: A viewpoint from Canada
Journal article published in 2012 by
Anthony S. Russell,
Vandana Ahluwalla,
Cheryl Barnabe 
,
Shahin Jamal,
Robert C. Offer,
Wojciech P. Olszynski,
Kam Shojania,
Boulos Haraoui
,
Shahin Jamal,
Robert C. Offer,
Wojciech P. Olszynski,
Kam Shojania,
Boulos Haraoui
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer term.